Pasithea Therapeutics (KTTA) Return on Sales (2022 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Return on Sales for 3 consecutive years, with 11.62% as the latest value for Q1 2024.
- Quarterly Return on Sales fell 1618.0% to 11.62% in Q1 2024 from the year-ago period, while the trailing twelve-month figure was 11.62% through Mar 2024, down 630.0% year-over-year, with the annual reading at 4.54% for FY2022, 13977.0% up from the prior year.
- Return on Sales hit 11.62% in Q1 2024 for Pasithea Therapeutics, down from 1.58% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 4.56% in Q1 2023 to a low of 34.5% in Q2 2022.
- Historically, Return on Sales has averaged 8.5% across 3 years, with a median of 2.84% in 2023.
- Biggest five-year swings in Return on Sales: skyrocketed 3402bps in 2023 and later tumbled -1618bps in 2024.
- Year by year, Return on Sales stood at 4.42% in 2022, then skyrocketed by 64bps to 1.58% in 2023, then plummeted by -638bps to 11.62% in 2024.
- Business Quant data shows Return on Sales for KTTA at 11.62% in Q1 2024, 1.58% in Q4 2023, and 2.84% in Q3 2023.